Holen Sie sich die Stockscreener-App
31.07
0.13%
-0.095
Überblick
Nachrichten
Preisverlauf
Optionskette
Financials
Warum fällt HROW?
Forum
Prognose
Aktiensplit
Harrow Inc Aktie (HROW) Neueste Nachrichten
HARROW HEALTH SHAREHOLDER ACTION REMINDER: Securities Litigation Partner James (Josh) Wilson Encourages Investors Who Suffered Losses Exceeding $50,000 In Harrow Health To Contact Him Directly To Discuss Their Options - The Globe and Mail
BTIG Initiates Harrow at Buy With $62 Price Target - marketscreener.com
BTIG Initiates Coverage of Harrow (HROW) with Optimistic Outlook | HROW Stock News - GuruFocus
Harrow Inc. sees $923,827 in stock sales by major shareholder - Investing.com South Africa
William Blair Bullish On Harrow's High-Margin Branded Eye Drug Strategy - Benzinga
Harrow wins new Outperform at William Blair after licensing deal for pain drug - MSN
HARROW HEALTH INVESTOR ALERT: Securities Litigation Partner James (Josh) Wilson Encourages Investors Who Suffered Losses Exceeding $50,000 In Harrow Health To Contact Him Directly To Discuss Their Options - The Globe and Mail
Harrow acquires U.S. commercial rights to BYQLOVI from Formosa Pharmaceuticals - MSN
Harrow (HROW) Gains Coverage with Outperform Rating Following Licensing Deal - GuruFocus
Harrow stock wins William Blair's new Outperform (HROW:NASDAQ) - Seeking Alpha
Assessing Harrow: Insights From 4 Financial Analysts - Benzinga
William Blair Initiates Coverage on Harrow (HROW) with Outperfor - GuruFocus
William Blair Initiates Coverage on Harrow With Outperform Rating - marketscreener.com
William Blair Initiates Outperform Rating for Harrow (HROW) | HROW Stock News - GuruFocus
Harrow Acquires U.S. Commercial Rights to BYQLOVI™ (Clobetasol Propionate Ophthalmic Suspension) 0.05% from Formosa Pharmaceuticals - mx.advfn.com
Harrow Acquires US Commercial Rights for Byqlovi From Formosa Pharmaceuticals - marketscreener.com
Harrow (HROW) Secures U.S. Rights to BYQLOVI - GuruFocus
Harrow (HROW) Secures Exclusive U.S. Rights for New Ophthalmic Steroid | HROW Stock News - GuruFocus
Harrow Acquires U.S. Commercial Rights To Byqlovi(TM) From Formosa Pharmaceuticals - marketscreener.com
HROW Signs Licensing Agreement for Exclusive U.S. Rights to Byqlovi 0.05% | HROW Stock News - GuruFocus
UBS AM a distinct business unit of UBS ASSET MANAGEMENT AMERICAS LLC Acquires 29,262 Shares of Harrow, Inc. (NASDAQ:HROW) - Defense World
Harrow Inc (HROW) Shares Down 5.39% on Jun 5 - GuruFocus
Bank of America Corp DE Trims Stock Holdings in Harrow, Inc. (NASDAQ:HROW) - Defense World
Millennium Management LLC Sells 101,671 Shares of Harrow, Inc. (NASDAQ:HROW) - Defense World
B. Riley Issues Pessimistic Forecast for Harrow Earnings - Defense World
Insiders Favor Harrow And 2 Other Leading Growth Companies - Yahoo Finance
Harrow Inc (HROW) Shares Up 4.04% on May 30 - GuruFocus
Obituary for Douglas "Doug" A. Harrow - Schaffer Funeral Home, Inc.
Harrow: Epic Growth & Operating Leverage On Full Display (NASDAQ:HROW) - Seeking Alpha
Harrow Inc (HROW) Stock Price Down 3.78% on May 22 - GuruFocus
Deutsche Bank AG Has $3.63 Million Holdings in Harrow, Inc. (NASDAQ:HROW) - Defense World
The Manufacturers Life Insurance Company Has $372,000 Holdings in Harrow, Inc. (NASDAQ:HROW) - Defense World
Harrow Inc (HROW) Stock Price Up 8.35% on May 16 - GuruFocus
Harrow Inc.: Opaleye management sells $150,055 in stock - Investing.com Australia
Harrow Inc.: Opaleye management sells $150,055 in stock By Investing.com - Investing.com India
Jim Cramer on Harrow, Inc. (HROW) – “Eye Care’s a Good Biz – If It Makes Money, Don’t Walk Away Pre-Breakout” - Insider Monkey
Harrow to Present at Two Investor Conferences in May - Business Wire
Jim Cramer Is 'OK' With Harrow, Recommends Buying This Energy Stock - Benzinga
Harrow Health, Inc. (NASDAQ:HROW) Q1 2025 Earnings Call Transcript - Insider Monkey
Harrow (HROW) Faces Price Target Cut Amid Q1 Earnings Miss | HRO - GuruFocus
HROW Stock Price Target Raised to $60 by Analyst | HROW Stock Ne - GuruFocus
Price T Rowe Associates Inc. MD Buys 1,428 Shares of Harrow, Inc. (NASDAQ:HROW) - Defense World
Harrow (NASDAQ:HROW) Price Target Raised to $60.00 at HC Wainwright - Defense World
Where Harrow Stands With Analysts - Benzinga
HROW Stock Update: Analyst Raises Price Target to $60 | HROW Sto - GuruFocus
Harrow (HROW) Reports Q1 Loss, Lags Revenue Estimates - MSN
Harrow Inc (HROW) Q1 2025 Earnings Call Highlights: Record Revenue Growth and Strategic Market ... - Yahoo Finance
Harrow Inc (HROW) Q1 2025 Earnings Call Highlights: Record Reven - GuruFocus
Harrow Inc (HROW) Q1 2025 Earnings Call Highlights: Record Revenue Growth and Strategic Market ... By GuruFocus - Investing.com Canada
Harrow Health Reports Strong Q1 2025 Revenue Growth - TipRanks
Harrow Announces First-Quarter 2025 Financial Results - BioSpace
Transcript : Harrow, Inc., Q1 2025 Earnings Call, May 09, 2025 - marketscreener.com
1.91%
1.56%
In Yahoo öffnen
|
In Google öffnen
|
In Finviz öffnen
|
In MarketWatch öffnen
|
Öffnen Sie in EDGAR
|
Offen in Reuters
Kapitalisierung:
|
Volumen (24h):